Publications

This Q&A provides a high-level overview of key practical issues, including life sciences clinical trials, manufacturing, marketing, abridged procedure, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, borderlines, and natural health products.

DLA Piper is a leading participant in the nascent cannabis industry; from start-up to private and public fundraisings, acquisition and post-merger, we are there to advise and help clients navigate uncertain waters. We have observed a number of divergent streams materialising from the shifting tectonic plates of cannabis regulation across the globe.